Evidence map›Paper›PMID 28939065›Full record

ArticleOral oncology2017

Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer.

Karen S Anderson, Garrick Wallstrom, Hilde Langseth, Marshall Posner, Julia N Cheng, Rizwan Alam, Diego Chowell, Ingegerd E Furre, Jon Mork

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Screening for oropharyngeal cancer: the time is now.Expert review of molecular diagnostics · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Oral manifestations of human papillomavirus infections.European journal of oral sciences · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Karen S AndersonCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States. Electronic address: Karen.Anderson.1@asu.edu.
Garrick WallstromCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Hilde LangsethCancer Registry of Norway, Institute of Population-based Cancer Research,; Department of Research, Oslo, Norway.
Marshall PosnerTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, United States.
Julia N ChengCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Rizwan AlamCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Diego ChowellCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States; Simon A. Levin Mathematical, Computational, and Modeling Sciences Center, Arizona State University, Tempe, AZ, United States.
Ingegerd E FurreDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Jon MorkDepartment of Otolaryngology, Oslo University Hospital, Oslo, Norway.
Arizona State University · USOslo University Hospital · NO657 Oslo · NOIcahn School of Medicine at Mount Sinai · US

Funding

Biomarker Detection Using NAPPA Tumor Antigen ArraysU01CA117374 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ANDERSON, KAREN SUE, LABAER, JOSHUA · 2005 to 2015
$6.2M
NCI NIH HHS U01 CA117374
6 · The paper itself

Abstract

objectiveThe aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis.

methodsWe identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3years before diagnosis (range, 0.1-14.9years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied.

resultsHPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3-7.2, p<0.0001). Abs to E2 were strongly associated with cases 0-2years pre- diagnosis (OR, 150.1; 95% CI, 27.4-1040.0, p<0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6-0.9, p=0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7-200.0, p<0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6-53.4) compared with controls (p<0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6-99.6, p<0.001).

conclusionsHPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.

Indexed as

AdultAntibodies, ViralFemaleHuman papillomavirus 16HumansImmunoglobulin GMaleMiddle AgedOropharyngeal NeoplasmsRisk FactorsAntibodies, ViralImmunoglobulin GAntibodiesBiomarkerHead and neck cancerHPVOropharyngeal cancerSerology

Identifiers

PMID28939065
PMCPMC5624546
OpenAlexW2750921080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.